129
Participants
Start Date
February 28, 2009
Primary Completion Date
October 31, 2010
Study Completion Date
October 31, 2010
AIGIV 3.5 mg/kg
AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.
Gamunex 90 mg/kg
Gamunex 90 mg/kg total IgG as a single intravenous infusion.
AIGIV 7.0 mg/kg
AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.
Gamunex 180 mg/kg
Gamunex 180 mg/kg total IgG as a single intravenous infusion.
AIGIV 14.0 mg/kg
AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
Gamunex 360 mg/kg
Gamunex 360 mg/kg total IgG as a single intravenous infusion.
SNBL Clinical Pharmacology Center Inc., Baltimore
Lead Sponsor
National Institutes of Health (NIH)
NIH
Emergent BioSolutions
INDUSTRY